It is made available under a CC-BY-NC-ND 4.0 International license .

## 1 Diagnostic signature for Heart Failure with Preserved Ejection Fraction (HFpEF): A

### 2 Machine Learning Approach Using Multi-Modality Electronic Health Record Data

- 3 Short Title: Diagnosis of HFpEF: A Machine Learning Approach
- 4 Nazli Farajidavar,<sup>1</sup>\* Kevin O'Gallagher,<sup>1,4</sup>\* Daniel Bean,<sup>1,2,3</sup> Adam Nabeebaccus,<sup>1,4</sup> Rosita
- 5 Zakeri,<sup>1,4</sup> Daniel Bromage,<sup>1,4</sup> Zeljko Kraljevic,<sup>2</sup> James TH Teo,<sup>4</sup> Richard J Dobson,<sup>1,2,3,5</sup> Ajay M
- 6 Shah. $^{1,4}$
- 7 \*joint authors
- 8
- <sup>9</sup> <sup>1</sup>King's College London British Heart Foundation Centre of Excellence, School of
- 10 Cardiovascular Medicine & Sciences, London, UK;
- <sup>2</sup>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and
- 12 Neuroscience, King's College London, London, UK;
- <sup>13</sup> <sup>3</sup>Health Data Research UK London, Institute of Health Informatics, University College London,

14 London, U.K

- <sup>4</sup>King's College Hospital NHS Foundation Trust, London, UK;
- <sup>16</sup> <sup>5</sup>NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and
- 17 King's College London, London, UK.
- 18
- 19 Correspondence: Prof Ajay M Shah, School of Cardiovascular Medicine & Sciences, King's
- 20 College London, James Black Centre, 125 Coldharbour Lane, London SE5 9NU, UK. Tel: 0044-
- 21 207848-5189. Email: ajay.shah@kcl.ac.uk

It is made available under a CC-BY-NC-ND 4.0 International license .

### 22 Word count: 3414

#### 23 ABSTRACT

- 24 Aims: Heart failure with preserved ejection fraction (HFpEF) is thought to be highly prevalent
- 25 yet remains underdiagnosed. We sought to develop a data-driven
- 26 diagnostic model to predict from electronic health records (EHR) the likelihood
- of HFpEF among patients with unexplained dyspnea and preserved left ventricular EF.

28 Methods & Results: The derivation cohort comprised patients with dyspnea and

29 echocardiography results. Structured and unstructured data were extracted using an automated

30 informatics pipeline. Patients were retrospectively diagnosed as HFpEF (cases), non-HF

31 (control cohort I), or HF with reduced EF (HFrEF; control cohort II). The ability of clinical

32 parameters and investigations to discriminate cases from controls was evaluated by extreme

33 gradient boosting. A likelihood scoring system was developed and validated in a separate test

34 cohort.

The derivation cohort included 1585 consecutive patients: 133 cases of HFpEF (9%), 194 non-HF cases (Control cohort I) and 1258 HFrEF cases (Control cohort II). Two HFpEF diagnostic signatures were derived, comprising symptoms, diagnoses and investigation results. A final prediction model was generated based on the averaged likelihood scores from these two models. In a validation cohort consisting of 269 consecutive patients (with 66 HFpEF cases (24.5%)), the diagnostic power of detecting HFpEF had an AUROC of 90% (P<0.001) and average precision (AP) of 74%.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 42 **Conclusion:** This diagnostic signature enables discrimination of HFpEF from non-cardiac
- 43 dyspnea or HFrEF from EHR and can assist in the diagnostic evaluation in patients
- 44 with unexplained dyspnea.

45

46 **Key words:** HFpEF, machine learning, dyspnea

It is made available under a CC-BY-NC-ND 4.0 International license .

# 47 INTRODUCTION

48 Heart Failure with preserved ejection fraction (HFpEF) is a highly prevalent yet under-diagnosed clinical syndrome [1, 2]. The hallmarks are the signs and symptoms of heart failure (HF) and a 49 50 preserved left ventricular ejection fraction (LVEF). HFpEF is thought to be underpinned by 51 structural and functional abnormalities of both the heart and vasculature. Patients with HFpEF 52 typically display diastolic dysfunction [3, 4] and other abnormalities such as vascular 53 stiffening[5] and impaired ventricular-vascular coupling[6-10]. Unlike HF with reduced Ejection 54 Fraction (HFrEF), no evidence-based therapies are available for HFpEF[11-13]. This may in part reflect the heterogeneity of HFpEF pathophysiology as well as issues of clinical trial 55 56 design[13-15].

57 While the diagnosis of HFpEF is straightforward in acutely decompensated patients, stable euvolemic patients present a greater challenge<sup>[16]</sup>. Exertional dyspnea and fatigue are non-58 59 specific symptoms that occur in many other conditions, including obesity and physical deconditioning. Expert transthoracic echocardiography (ideally with exercise) or invasive cardiac 60 catheterization to document raised LV filling pressures may not be immediately available to the 61 62 non-specialist. A recent study found that among more than 44,000 community-based patients 63 likely to have HF, only 50% had a documented LVEF[17]. Furthermore, those eventually 64 diagnosed as having HFpEF required many more pre-diagnosis investigations and consultations 65 than HFrEF patients.

In previous epidemiological studies, identification and extraction of HFpEF cases from
Electronic Health Records (EHR) has typically relied on diagnostic codes, additional medical
record abstraction, and/or adjudication based on various expert criteria e.g. European Society of

It is made available under a CC-BY-NC-ND 4.0 International license .

- 69 Cardiology criteria [18]. The EHR is however increasingly amenable to rapid and automated
- 70 extraction of multiple clinical parameters, including the use of advanced natural language
- 71 processing (NLP) algorithms to identify clinical concepts recorded in the unstructured text[19-
- 72 21].
- 73 The aim of this study was to extract and analyze data from the EHR to develop an automated
- 74 approach to identify patients likely to have HFpEF.
- 75

It is made available under a CC-BY-NC-ND 4.0 International license .

## 76 METHODS

## 77 Approvals

78 This project was conducted under London South East Research Ethics Committee approval

79 (reference 18/LO/2048) granted to the King's Electronic Records Research Interface (KERRI),

80 project ID 202020201.

### 81 Derivation Cohort

82 We performed a retrospective study using de-identified data of patients attending King's College

Hospital NHS Foundation Trust (KCH) in London (UK) between 2000 and 2019. We focused on

patients who had undergone echocardiography as part of their inpatient or outpatient evaluation.

85 With this starting point, a number of different patient cohorts were derived based on the LVEF,

confirmed or possible HF, symptoms of dyspnea, and NT-proBNP (or BNP) level (see

87 Supplementary materials Sections I and II). We identified confirmed HFpEF cases and two

88 control cohorts: those with no evidence of HF (non-HF, Control cohort I) and those with HFrEF

89 (Control cohort II). HFpEF cases were defined as patients with a preserved LVEF  $\geq$  50% (with

90 no evidence of LVEF <50% at any stage), a confirmed diagnosis of HF based on discharge

91 ICD10 codes I50.0, I50.1 or I50.9, dyspnea, and a raised NT-proBNP or BNP level (according to

age-specific thresholds), in accordance with ESC diagnostic criteria[18]. Patients with valvular

heart disease (ICD10 codes I05-I09 and I35) were excluded.

## 94 Test Cohorts

95 We generated 4 test cohorts from patients who lacked at least one of the above diagnostic

96 features for a confirmed diagnosis of HFpEF (see Supplementary Table S1 and Flowchart S1).

97 We randomly sampled 100 patients from each of these four test subsets for analysis and removed

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266560; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

samples where the clinical annotations disagreed or there was more than 70% missingness in
signature predictors, leaving 269 in total.

## 100 Data extraction and evaluation

101 Clinical and demographic data were retrieved from the structured and unstructured components 102 of the EHR using the CogStack informatics platform [20]. Automated parsing of the EHR was 103 achieved with a state-of-the-art enterprise search and well-validated natural language processing 104 (NLP) tools, including MedCAT[22] and the Unified Medical Language System repository[23] 105 as previously used by our group.[24] Clinical term extraction was restricted to concepts which 106 represent clinical findings, diseases (apart from HF), medications, and signs and symptoms. This 107 was linked to searches of structured data from an internal database containing echocardiographic data and ICD codes. Continuous variables were cleaned prior to cohort selection; e.g. conversion 108 109 of text references of LVEF to numerical values and removal of measurement outliers (see 110 **Supplementary material Section III**). We used both platforms to arbitrate discrepancies in our derivation dataset as neither source proved to be comprehensive, in line with previous work [20, 111 21]. 112

Echocardiographic data were based on studies performed according to British Society of Echocardiography guidelines[25] (which are consistent with American and European guidelines)[26]. Structured data recorded in echocardiography results were boosted with numerical data reported in the EHR text. Additionally, when appropriate (e.g. patient had echocardiography but a numerical value for LVEF was not documented) we used a deep learning model to infer whether the LVEF was preserved based on the echocardiography report (see **Supplementary materials Section III**).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 120 BNP or NT-proBNP results were obtained from samples drawn at any time in the study period
- 121 and the maximum value for each subject was used.
- 122 All cases in the derivation dataset that were identified by the data pipeline as HFpEF were
- 123 validated by manual review of the EHR by a cardiologist.

124

# 125 Potential modeling predictors

A binary diagnostic outcome indicating the presence or absence of HFpEF was considered for 126 127 modeling. Potential predictors to be included in a diagnostic signature included those used in 128 previous HFpEF epidemiological studies [14, 15]. In addition, we adopted a comprehensive 129 approach that included physiological variables, laboratory results, echocardiographic data and clinical concept references [27]. Structured data were collected within a two-month temporal 130 131 window around the last echocardiography result (or NTproBNP/BNP test result if available). 132 Unstructured data were analyzed from the entire EHR prior to the date of the echocardiography 133 result for each patient.

We made a second level predictor grouping according to whether the variables were initially recorded as (a) structured data: demographic and physiological parameters, and laboratory and echocardiography measurements; or (b) unstructured text in the EHR, extracted via the NLP platform. We adopted the bag-of-words[28] approach to transform clinical concept annotation into word vectors for modeling purposes. Concepts which were mentioned in <10% of the derivation cohort were excluded. Data from the other predictor categories were collected and imputed prior to training, using the k-nearest neighbor (Scikit-learn python package v0.22) after medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266560; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

141 min-max normalization. Following imputation, data items were rescaled into their original range142 to preserve the explainability of the final model.

#### 143 Data modelling, feature selection and validation

We used the tree-based multivariable extreme gradient boosting[29] algorithm (XGBoost, python package v0.9) for modeling, enabling inclusion of mixed data types and smooth handling of missing values and sparsity issues. As such, when a value is missing in the sparse predictor vector, the instance is classified into a default direction (see[29] for further details) that is learnt

148 as optimal using derivation data.

149 SHAP[30] analysis (SHapley Additive exPlanations; SHAP python package v0.33) was used to

150 order the predictors according to their prominence in discriminating cases from controls. Once

the full model was created, we took a stepwise forward insertion scheme to include the

152 more significant variables one at a time, in order to determine the minimal number of predictors

that gave an acceptable performance relative to the use of all predictors. The final predictive

154 models were trained and evaluated using the obtained optimal subset of predictors.

Model validation was undertaken in the test cohorts described earlier, using clinical assessment criteria from the H<sub>2</sub>FPEF score[16] as a comparator. A random sample of 400 patients from the test datasets was manually reviewed by two teams each comprising two cardiologists, in order to validate diagnoses. Any cases of clinician disagreement were removed from the evaluation, leaving a total of 269 patients in the test datasets (see Results, **Table 1**).

#### 160 Statistical analysis of predictors

Data are presented as mean and standard deviation (SD) or median and interquartile range (IQR) as appropriate. Differences between cases and controls were evaluated by the Mann-Whitney U test or unpaired t test, as appropriate. The area under the receiver-operating characteristic curve (AUROC), F1-score (macro and weighted<sup>2</sup>) and average precision (AP) were used as performance metrics.

A stratified 5-fold cross-validation scheme (to ensure each fold is a good representative of the whole data in terms of class prevalence) was utilized for feature selection and derivation set validation. As such, the derivation data was divided into five subsets, four of which were used for training the model and the final one for validation/testing. The derivation and test subsets were shuffled until all five subsets were evaluated. The final performance was then reported as mean and standard deviation of all five tests.

The AUROC and AP were used as performance metrics and the Kappa statistic was used to
measure the inter-rater agreement of proposed models. All tests were 2-sided, with P<0.05</li>
considered significant.

To evaluate the generalizability of the model to a new sample, Harrell optimism was calculated with 1000 boot-strap replicates[31]. To evaluate discrimination power of the proposed model beyond existing criteria, we compared the model's AUROCs and AP performance against the recently proposed H<sub>2</sub>FPEF scoring system[16] using the Random Forest (predecessor to XGBoost).

180 Statistical analyses were performed in Python 3 using SciPy and Scikit-learn packages (v0.22).

### 181 Data availability

It is made available under a CC-BY-NC-ND 4.0 International license .

- 182 The data included in the study will not be made available to other researchers due to hospital
- information governance regulations. However, we will share our models and the analytical
- 184 methods to facilitate the replication of the study on data collected from other hospitals.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 186 **RESULTS**

187 1854 patients were included in the study of whom 1585 were in the derivation cohort (Table 1).
188 HFpEF patients in the derivation cohort (n=133) were older than those with non-HF or HFrEF,
189 with a higher proportion of females and a higher BMI. They also had a higher prevalence of
190 hypertension, atrial fibrillation, diabetes and chronic kidney disease. Systolic and diastolic
191 pressures were higher in the HFpEF group compared to HFrEF. Patients with HFpEF had lower
192 end-diastolic and end-systolic volumes and higher septal E/e' ratios than the non-HF control
193 group.

194

#### 195 Structured, unstructured and combined signatures for HFpEF diagnosis

We initially divided the predictors into two sets based on the source of data being structured data 196 197 or clinical concepts and conditions extracted from the unstructured historical EHR (see 198 Methods). We excluded the BNP/NT-proBNP assessment data and HF concept references from 199 both predictor sets to avoid biasing models by information on outcome. Separate 200 XGBoost models were trained on each predictor set. SHAP analysis was adopted to select the 201 optimal number of features from each predictor set using five-fold cross-validation. We then 202 compared the discriminant power of these signatures to distinguish HFpEF cases either from 203 non-HF patients (Control set I) or HFrEF patients (Control set II).

The minimum number of variables required to maintain an acceptable level of performance for each model were selected (**Figure 1**). Following an early-fusion modeling strategy, we merged the selected predictors from the two sets of structured and unstructured variables and trained

It is made available under a CC-BY-NC-ND 4.0 International license .

an XGBoost model for discrimination and termed the derived signature as the combinedsignature.

209 SHAP analysis to assess feature importance showed that individual predictors had different value

210 in discrimination of HFpEF versus non-HF or HFrEF (**Figure 2**). For example, dyspnea and

211 pharmacologic substance were the most prominent predictors in discrimination against non-HF

212 whereas EF was most important for discrimination against HFrEF. However, many of the

features (e.g. age, patient address) were common to the two groups. The text references to

"214 "patient address" and "pharmacologic substance" were surrogate predictors of the number of

215 complete hospital admissions. (Figure 2).

216 The combined signature model for discrimination of HFpEF from HFrEF showed an enhanced

AUROC performance and F1-measure score as compared to the single-view models in the 5-fold

cross-validation evaluation in our developmental dataset (**Table 2**). The performance

enhancement of the combined model in discriminating HFpEF from non-HF was less significant.

220 This was due to dominancy of the unstructured predictors in this combined signature (see Figure

221 **2** and **Table 3**).

# 222 Selection of the final model and evaluation in test cohorts

The final model that was used for test evaluations aggregates the HFpEF vs HFrEF and HFpEF vs non-HF signature likelihood predictions, through an averaging operation. We used this aggregate model to make predictions on the test sets. **Figure S5** summarises the entire processing and model training pipeline.

It is made available under a CC-BY-NC-ND 4.0 International license .

To address the distributional variation between training and test cohorts which was caused by sample selection bias, we used 30% of the test samples (test1: 19, test2: 21, test3: 17, test4: 23) to retune the models, following the domain adaptation transfer learning technique[32]. Details of the 30% choice of adaptation set size is included in the **Supplementary materials, Figure S6**.

231 The performance of both proposed base models and the final aggregated model remained robust

in the test cohort as compared to expert clinical consensus, with an AUROC performance of 0.86

233 (95% CI,  $\pm$  0.002) and 0.85 (95% CI,  $\pm$  0.001) in HFpEF vs non-HF and HFpEF vs HFrEF

models, respectively and an enhanced aggregate performance of 0.90 (95% CI,  $\pm$  0.002) in our

final aggregate model (**Figure 3**).

Lastly, we compared the final aggregate model as well as the baseline combined signature

237 models (discriminating against non-HF or HFrEF) with the recently described H<sub>2</sub>FPEF

model[16]. The AUROC and average precision of both the aggregate model and the individual

baseline models was higher than the H<sub>2</sub>FPEF model (**Table 4**). We additionally used the Cohen's

kappa score to report on the agreement between the predictions made by our proposed models to

better highlight the efficiency of the aggregate model over the individual base models

242 discriminating HFpEF from non-HF and HFrEF. The positive kappa score of 0.3 indicates a

243 weak agreement between the two base models. This was expected as the test cohort had lower

availability of clinical assessments compared to the derivation cohort.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 246 **DISCUSSION**

247 In this study, we have developed an automated pipeline for EHR-based data collection,

processing and modeling to identify patients with a high likelihood of HFpEF. We incorporated multi-modality data, including both structured and unstructured predictors, to generate a disease diagnostic signature. The proposed signature was validated in a separate cohort of patients and performed favourably as compared either to expert clinical consensus or the recently proposed H<sub>2</sub>FPEF score [16].

Analysis of the signatures that distinguished HFpEF from non-cardiac causes of dyspnea (non-253 254 HF) revealed anticipated predictors such as atrial fibrillation, hypertension, diabetes mellitus, 255 kidney failure and obesity, in accordance with previous literature [16]. In addition, surrogate 256 measures of multiple previous clinical encounters detected by the NLP algorithm as frequent text 257 references to terms such as "pharmacologic substance" or "patient address" were very useful. 258 This may reflect the fact that patients with HFpEF may require multiple clinical visits and 259 investigations, often with different specialities, before a diagnosis is established [17]. Apart from 260 LVEF itself, features that distinguished HFpEF from HFrEF included age, peripheral edema, and 261 other echocardiographic measures. An advantage of the approach that we employed may be that 262 it is unbiased and comprehensive and identifies variables for inclusion in the diagnostic signature 263 based purely on the results of the objective feature selection process. This may be one reason 264 why our algorithm outperforms the H<sub>2</sub>FPEF score, which is based on the evaluation of selected 265 variables rather than a comprehensive unbiased analysis. In this regard, it is of interest that 266 echocardiographic predictors that contributed to the differentiation of HFpEF from HFrEF 267 included maximum flow velocity across the aortic valve, aortic insufficiency and LA volume 268 whereas  $E/e^{2}$  (which is part of the H<sub>2</sub>FPEF score) did not feature in the top 30 predictors.

It is made available under a CC-BY-NC-ND 4.0 International license .

269 A major underlying problem in efforts to develop or test new treatments for HFpEF is the 270 difficulty in consistently diagnosing the syndrome [17]. Many different approaches are used in 271 the literature based on varying criteria published by national and international societies, and 272 diverse inclusion criteria have been used in clinical trials 33-35. The problem is compounded by 273 the likelihood that HFpEF is a heterogenous syndrome in which sub-populations may have differing underlying pathophysiology and outcomes [14, 15, 33]. The approach we present 274 275 enables rapid identification of likely HFpEF cases among which further specific phenotyping 276 could be performed to refine the diagnosis and potentially test or target defined interventions, or 277 to identify potential subjects for research studies. Importantly, this approach aims to identify 278 both compensated and decompensated HFpEF cases, using an automated and data-driven approach that is effective even where structured data (e.g. NT-proBNP measurements) are 279 280 scarce. The approach may be considered complementary to scores such as H<sub>2</sub>FPEF. Our 281 signature is ideally suited to rapidly identify a large number of possible HFpEF cases from EHR 282 whereas H2PEF is better suited for use by the clinician evaluating an individual patient who is 283 suspected to have HFpEF.

This study is the first to use SHAP analysis for feature selection in this context. We comprehensively validated all variations of the derived models in multiple datasets with underlying variational distributions. We demonstrated a significant improvement in HFpEF diagnostic performance when discriminating the patients with HFpEF from those with HFrEF or no HF history. A key strength of our approach is that modeling numerical assessment data (structured results signature) and EHR concept references separately makes the models applicable in scenarios where one of these sources of data may be scarce. Moreover, the dual

It is made available under a CC-BY-NC-ND 4.0 International license .

291 modeling of HFpEF separation from non-HF and HFrEF subjects increases the utility of the

292 proposed pipeline in distinguishing among a wider group of clinical conditions.

293

## 294 Limitations

295 The UMLS clinical concept encoding that was used to extract unstructured observations does not 296 support distinct encoding of different disease stages and could therefore cause some inaccuracy. 297 In a more general aspect, the *a priori* assumptions that we made to identify definite HFpEF cases 298 in the derivation dataset influenced the characterisation of the cohort. For example, we utilised 299 ICD-10 diagnostic codes in the identification of patients with heart failure. Previous studies 300 have demonstrated inaccuracy in identifying incident heart failure using ICD-10 coding as the 301 sole source[36]. It is possible that such inaccuracy is present in our coding system; however the 302 use of additional features (symptoms, LVEF, BNP/NTproBNP) in case classification mitigates 303 this risk in our study. The inclusion of a raised BNP criterion restricts the cohort to a subgroup 304 of HFpEF subjects, which was evident in test cohorts where many of the subjects did not have 305 BNP measurements. This issue could be successfully handled through transfer learning techniques but would require some labelled data from a new domain to facilitate such a feedback 306 307 training loop. The choice of data imputation technique could be another source of minor but 308 systematic error. The discriminant power of the model to detect HFpEF is lower in test subsets where the missing data rate is higher and HFpEF cases are a small proportion of the overall 309 310 number. Finally, the applicability of our model in patients with HFpEF who have never required 311 hospital evaluation or admission is unknown. However, a strength of our approach is that a 312 dedicated specialist assessment for HF is not required to assess the probability of HFpEF among 313 patients undergoing general hospital evaluation (e.g. non-cardiological), even in the absence of

It is made available under a CC-BY-NC-ND 4.0 International license .

314	commonly used diagnostic data such as NTproBNP levels. The lack of independent validation is
315	a limitation of this study. Evaluation of the derived model's performance in independent datasets
316	from other centres and in community-based datasets will be informative in future studies.
317	Although we compared performance of the model with the H <sub>2</sub> FPEF score,[16] due to its stated
318	aim of estimating the likelihood that HFpEF among patients with unexplained dyspnoea to guide
319	further testing, we did not compare performance to the HFA-PEFF algorithm[37] which is a
320	multi-step diagnostic algorithm. Furthermore, the comparison of our alogrithm's performance
321	with the H <sub>2</sub> FPEF should be confirmed in a separate validation cohort.
322	
323	Conclusion
324	In this study, we have developed a rapid and automated data-driven approach that is effective at

identifying patients from EHR who are likely to have HFpEF. This algorithm affords significant
potential to rapidly identify patients for more detailed analyses and/or potential inclusion in
clinical trials. The approach that we report could in principle be readily applied to other diseases
and conditions that are similarly difficult to diagnose.

329

330 Supplemental Materials. The supplementary digital content is provided to support the findings331 of this study.

332

333	Contributors
-----	--------------

334 Study design: NF, KO, RD, AMS;

It is made available under a CC-BY-NC-ND 4.0 International license .

- 335 Data collection: NF, JK, JO, AM;
- 336 Data modeling: NF, DB, RD;
- 337 Data analysis: NF, KO;
- 338 Clinical validation: KO, RZ, DB2, AN;
- Result interpretation and writing the paper: All authors.
- 340 Funding: AMS.
- 341 Supervision: RD and AMS.

## 342 Acknowledgements

- 343 We thank Ahmed Mahmmud and Joe Omigie for their invaluable advice during the data
- 344 collection phase and Norman Catibog and Thiago Fonseca for sharing their knowledge in
- echocardiography. This work was supported by the British Heart Foundation (RE/18/2/34213;
- 346 CH/1999001/11735); the NIHR Biomedical Research Centres at Guy's & St Thomas' NHS
- Foundation Trust (IS-BRC-1215-20006) and South London and Maudsley NHS Foundation
- Trust (IS-BRC-1215-20018), both with King's College London. KOG is supported by a Medical
- Research Council Clinical Training Fellowship (MR/R017751/1). DMB is funded by a UKRI
- Innovation Fellowship as part of Health Data Research UK MR/S00310X/1
- 351 (https://www.hdruk.ac.uk). The views expressed are those of the authors and not necessarily
- those of NIHR or the Department of Health and Social Care. The funders had no role in study
- design, data collection and analysis, decision to publish, or preparation of the manuscript.

354

# 355 Conflicts of Interest

356 The authors have no conflicts of interest to declare.

It is made available under a CC-BY-NC-ND 4.0 International license .

357

**Data Sharing** The raw data used in this research are not openly available.

359

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 361 **References**

362

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med*. 2006;**355**:251-259.

Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL.
 Systolic and diastolic heart failure in the community. *JAMA*. 2006;**296**:2209-2216.

367 3. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and 368 passive stiffness of the left ventricle. *N Engl J Med*. 2004;**350**:1953-1959.

Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van
 Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients
 with heart failure and a preserved ejection fraction: contributions of collagen and titin. *Circulation*.
 2015;**131**:1247-1259.

5. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. *Circulation*. 2003;**107**:714-720.

3766.Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load377studied in isolated canine ventricle. Am J Physiol. 1983;245:H773-780.

378 7. Leite-Moreira AF, Correia-Pinto J. Load as an acute determinant of end-diastolic pressure379 volume relation. *Am J Physiol Heart Circ Physiol*. 2001;**280**:H51-59.

3808.Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial381relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res. 1999;43:344-353.

Borlaug BA, Melenovsky V, Redfield MM, Kessler K, Chang HJ, Abraham TP, Kass DA. Impact of
arterial load and loading sequence on left ventricular tissue velocities in humans. *J Am Coll Cardiol*.
2007;**50**:1570-1577.

Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, Olson TP, Borlaug BA.
 Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. *J Am Coll Cardiol.* 2017;**70**:136-148.

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B,
 Ostergren J, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure
 and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*. 2003;**362**:777-781.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer
 MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B,
 Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF,
 Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, Investigators
 P-H, Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N
 Engl J Med. 2019;381:1609-1620.

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg
JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah
SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T. Spironolactone for heart failure with
preserved ejection fraction. *N Engl J Med*. 2014;**370**:1383-1392.

401 14. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo
402 RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation*.
403 2015;**131**:269-279.

It is made available under a CC-BY-NC-ND 4.0 International license .

Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. PhenotypeSpecific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. *Circulation*. 2016;**134**:73-90.

407 16. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based
408 Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. *Circulation*.
409 2018;**138**:861-870.

410 17. Huusko J, Purmonen T, Toppila I, Lassenius M, Ukkonen H. Real-world clinical diagnostics of 411 heart failure patients with reduced or preserved ejection fraction. *ESC Heart Fail*. 2020;**7**:1039-1048.

18. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;**37**:2129-

418 2200.

- Wu H, Toti G, Morley KI, Ibrahim ZM, Folarin A, Jackson R, Kartoglu I, Agrawal A, Stringer C, Gale
  D, Gorrell G, Roberts A, Broadbent M, Stewart R, Dobson RJB. SemEHR: A general-purpose semantic
  search system to surface semantic data from clinical notes for tailored care, trial recruitment, and
  clinical research. J Am Med Inform Assoc. 2018;25:530-537.
- 423 20. Jackson R, Kartoglu I, Stringer C, Gorrell G, Roberts A, Song X, Wu H, Agrawal A, Lui K, Groza T, 424 Lewsley D, Northwood D, Folarin A, Stewart R, Dobson R. CogStack - experiences of deploying integrated 425 information retrieval and extraction services in a large National Health Service Foundation Trust 426 hospital. *BMC Med Inform Decis Mak*. 2018;**18**:47.
- 427 21. Kraljevic Z BD, Mascio A, Roguski L, Folarin A, Roberts A, Bendayan R, Dobson R. MedCAT -428 medical concept annotation tool. 2019.
- 429 22. Kraljevic Z ST, Shek A, Roguski L, Noor K, Bean D, Mascio A, Zhu L, Folarin AA, Roberts A,
  430 Bendayan R, Richardson MP, Stewart R, Shah AD, Wong WK, Ibrahim Z, Teo JT, Dobson RJB. Multi431 domain Clinical Natural Language Processing with MedCAT: the Medical Concept Annotation Toolkit.
  432 2020.
- 433 23. (MD) B. UMLS Reference Manual 2009.
- 434 24. Bean DM, Teo J, Wu H, Oliveira R, Patel R, Bendayan R, Shah AM, Dobson RJB, Scott PA.
  435 Semantic computational analysis of anticoagulation use in atrial fibrillation from real world data. *PLoS*436 *One*. 2019;**14**:e0225625.
- 437 25. Wharton G, Steeds R, Allen J, Phillips H, Jones R, Kanagala P, Lloyd G, Masani N, Mathew T, 438 Oxborough D, Rana B, Sandoval J, Wheeler R, O'Gallagher K, Sharma V. A minimum dataset for a 439 standard adult transthoracic echocardiogram: a guideline protocol from the British Society of 440 Echocardiography. *Echo Res Pract*. 2015;**2**:G9-G24.
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E,
  Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT,
  Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults:
  an update from the American Society of Echocardiography and the European Association of
  Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;**16**:233-270.
- Bielinski SJ, Pathak J, Carrell DS, Takahashi PY, Olson JE, Larson NB, Liu H, Sohn S, Wells QS,
  Denny JC, Rasmussen-Torvik LJ, Pacheco JA, Jackson KL, Lesnick TG, Gullerud RE, Decker PA, Pereira NL,
  Ryu E, Dart RA, Peissig P, Linneman JG, Jarvik GP, Larson EB, Bock JA, Tromp GC, de Andrade M, Roger
  VL. A Robust e-Epidemiology Tool in Phenotyping Heart Failure with Differentiation for Preserved and
  Reduced Ejection Fraction: the Electronic Medical Records and Genomics (eMERGE) Network. J *Cardiovasc Transl Res.* 2015;**8**:475-483.

It is made available under a CC-BY-NC-ND 4.0 International license .

452 28. Major V, Surkis A, Aphinyanaphongs Y. Utility of General and Specific Word Embeddings for 453 Classifying Translational Stages of Research. *AMIA Annu Symp Proc.* 2018;**2018**:1405-1414.

454 29. Chen T GC. XGBoost: A Scalable Tree Boosting System. *KDD '16: Proceedings of the 22nd ACM* 455 *SIGKDD International Conference on Knowledge Discovery and Data Mining*. 2016:785-794.

456 30. Lundberg S S-IL. A unified approach to interpreting model predictions. *NIPS*. 2017.

457 31. Steyerberg EW, Harrell FE, Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal 458 validation of predictive models: efficiency of some procedures for logistic regression analysis. *J Clin* 459 *Epidemiol*. 2001;**54**:774-781.

460 32. Donahue J HJ, Rodner E, Saenko K, Darrell T. Semi-supervised Domain Adaptation with Instance
461 Constraints. 2013 IEEE Conference on Computer Vision and Pattern Recognition. 3012:668-675.

462 33. Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective.
 463 *Circ Res.* 2019;**124**:1598-1617.

Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P,
Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA,
Januzzi JL, Jr., Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM. Heart Failure With Preserved
Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. *JACC Heart Fail.* 2018;6:619-632.

469 35. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, Hardin KM, Zampierollo GA, 470 Jarolim P, Pappagianopoulos PP, Malhotra R, Nayor M, Lewis GD. Differential Clinical Profiles, Exercise 471 Responses, and Outcomes Associated With Existing HFpEF Definitions. *Circulation*. 2019;**140**:353-365.

472 36. Kaspar M, Fette G, Guder G, Seidlmayer L, Ertl M, Dietrich G, Greger H, Puppe F, Stork S. 473 Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and 474 discharge letter information. *Clin Res Cardiol*. 2018;**107**:778-787.

475 37. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, 476 Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD,

477 Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart

478 failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus

recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2020;**22**:391-412.

481

It is made available under a CC-BY-NC-ND 4.0 International license .

### 483 TABLES

484 Table 1. Baseline characteristics of patients. The mean and SD (standard deviation) were 485 obtained where the predictor distribution follows a normal distribution, whereas for predictors with a skewed distribution, the median and interguartile range  $(25^{\text{th}}-75^{\text{th}})$  were used to report the 486 statistics. To evaluate the distributional differences between cases and controls, the Mann-487 488 Whitney U test or the t test was acquired, where appropriate. Values in parentheses next to each 489 predictor name indicate the data availability percentage. 490 \* Constraint-free assumption on our test sets resulted in predictors with either a singular value or a high proportion of missing values. In such cases, the computation of common statistics was not 491 492 pragmatic and hence the NAN (Not A Number) value was reported, instead. \*\* This predictor is only computed in the test cohort to enable the comparison with the  $H_2$ FPEF 493 494 score. # 92.45% of HFpEF cases and controls had a BNP or pro-BNP level available. 495 Set I: patients with normal EF, no/normal BNP record, a HF ICD10 code and at least one HF and 496 497 dyspnea reference in their EHR. 498 Set II: patients with normal EF, no/normal BNP record, no HF diagnostic code and at least one 499 HF and dyspnea reference in their EHR. Set III: patients with normal EF, no BNP record, no HF diagnostic code nor HF reference in the 500 501 EHR, at least one report of their dyspnea in their EHR. 502 Set IV: patients with normal EF, raised BNP result with HF and dyspnea reference in their EHR but no HF diagnosis documented 503

It is made available under a CC-BY-NC-ND 4.0 International license .

- 504 (HF: heart failure, EF: ejection fraction, rEF: reduced EF, BNP: brain-natriuretic peptide test,
- 505 EHR: electronic health record).
- 506 The following ICD10 codes were used to define the comorbidities:
- 507 Hypertension: I10-I15, I60-I69; Diabetes mellitus: E10-E14; Atrial fibrillation: I48; Pulmonary
- 508 hypertension: I27; Kidney Disease: N18, N28, I12-I15

509

Table 2. Multivariable model performance using the 5-fold cross-validation in derivation
dataset.

512

- 513 **Table 3. Additive SHAP feature importance for each category of predictors in the**
- 514 combined signatures.

515

- 516 **Table 4**. **Multivariable model performance in independent test cohort.** The 95% CI is
- 517 reported using bootstrapping in a thousand of iterations.
- \*: HFpEF annotation agreement between the two scoring systems using Cohen's kappa statistics
- 519 (python 3, Sklearn v.0.22).
- AUROC: area under receiver operative curve, AP: average precision, CI: confidence interval in
  bootstrapped samples

It is made available under a CC-BY-NC-ND 4.0 International license .

# 523 FIGURES

524	Figure 1.	Feature selection analy	sis. Features	were incremental	ly utilized	for training the
					1	

- models to ensure a performance within  $\pm 2$  units of the AUROC and f1-macro metrics in 5-fold
- 526 cross-validation setup. Blue: f1-macro, Red: AUROC

## 527 Figure 2. Feature importance using SHAP analysis in combined signatures. Denser

- 528 distribution of red points at the positive quadrant of the plot is representative of higher values of
- a given predictor's contribution in characterizing the positive class distribution i.e. in
- 530 characterizing HFpEF.

# 531 Figure 3. Performance of base and aggregate models. Panel A: Receiver Operating

532 Characteristic curves for base models, aggregate model, and H<sub>2</sub>FPEF score. Panel B: Precision

- 533 Recall curves for base models, aggregate model, and H<sub>2</sub>FPEF score. Panel C: Calibration curve
- for aggregate model. Panel D: Efficiency curve for aggregate model. Panel E: Aggregate model
- 535 performance in the 4 test subsets

536



Figure 1. Feature selection analysis. Features were incrementally utilised for training the models to ensure a performance within ±2 units of the AUROC and f1-macro metrics in 5-fold cross-validation setup. Blue: f1-macro, Red: AUROC



Figure 2. Feature importance using the SHAP analysis in combined signatures: denser distribution of red points at the positive quadrant of the plot is representative of higher values of a given predictor's contribution in characterizing the positive class distribution i.e. in characterizing HFpEF.



Figure 3. Performance of base and aggregate models. Panel A: Receiver Operating Characteristic curves for base models, aggregate model, and H2FPEF score. Panel B: Precision Recall curves for base models, aggregate model, and H2FPEF score. Panel C: Calibration curve for aggregate model. Panel D: Efficiency curve for aggregate model. Panel E: Aggregate model performance in the 4 test subsets

It is made available under a CC-BY-NC-ND 4.0 International license .

n	1	1		1	1			
	Non-HF	HFrEF	HFpEF	Pvalue		Test c	ohorts	
	controls	controls	cases	cases vs	(n:	(n=269, HFpEF cases = 68)		
	(n =194)	(n=1258)	(	controls				
			(n =133)					
					Set	Set II	Set III	Set IV
					(n=61)	(n=68)	(n=71)	(n=69)
Female, % (100%)	48.5%	36.8%	54.9%	-	61.8%	67.1%	68.9%	61.2%
Age,y(100%)	54 ± 18	69 (22)	73 ± 12	<0.0001	66±13	56±15	55±15	61±13
Body mass index,	28.35 ±	28.75 ±	34.06 ±	<0.0001	30.95 ±	32.18	30.66 ±	31.67 ±
kg/m <sup>2</sup> (76%)	8.07	7.34	10.07		8.15	± 8.32	7.58	7.87
Hypertension, %	43.2%	81.6%	91.7%	-	83.8%	89.5%	67.6%	79.6%
Diabetes mellitus, %	20.1%	42%	54.1%	-	52.9%	31.6%	24.3%	34.7%
Atrial fibrillation, %	4.6%	47.6%	52.6%	-	50%	19.7%	6.7%	37.8%
Pulmonary	<1%	12.2%	25.6%	-	26.5%	7.9%	2.7%	11.2%
hypertension, %								
Kidney	6.7%	35.5%	46.6%	-	66.1%	21.1%	24.3%	25.5%
,								
disease, %								
Antihypertensive	-	-	-	-	2(10)	0(4)	0(4)	0(0)
drugs, n**								
			1		1			
NT-proBNP, pg/m	46 (53)	138	4181	-	873	282	NAN*	781
(#)		(10/0)	(3620)		(1359)	(181)		(1258)
BNP, pg/m	54 (73)	76 (353)	1510	-	NAN*	NAN*	NAN*	796
(#)			(4488)					(656)
\"7								
Creatinine, umol/l	82.8 ±	88.0	84.0	0.165	89.0	78.0	78.5	86.6 ±
(99%)	39.7	(34.0)	(28.0)		(40.0)	(25.5)	(24.0)	19.6
Hemoglobin g/d	126+21	133(26)	131+18	0.836	127+	128+	126+	129+
(96%)	1210 2211	10.0 (2.0)	10.1 1 1.0		2.0	1.7	2.0	2.1
			7.45					
White cell count, $10^9/1(100\%)$	/.1 (4.33)	/.54 (2.90)	/.43 (2.76)	0.141	6.94	6.64	7.28 (7.72)	6./4
10 / (100%)		(ביב)	(5./0)		(5.57)	(3.4)	(4.45)	(2.10)

It is made available under a CC-BY-NC-ND 4.0 International license .

C-reactive protein, mg/l (96%)	6.5 ± 3.21	6.87 ± 3.12	7.4 (5.0)	0.254	6.93 ± 3.17	6.34 ± 3.01	6.62 ± 3.03	6.12 ± 3.11
Urea, mmol/l (99%)	5.73 ± 3.73	7.12 ± 4.43	6.4 (3.7)	0.687	6.85 (3.98)	5.3 (1.85)	4.65 (2.47)	5.95 (2.43)
Albumin, g/l (99%)	40.17 ± 6.98	41.13 ± 6.52	42.0 (3.0)	0.711	41.0 (6.0)	42.5 (4.25)	43.0 (6.0)	43.0 (3.0)
Sodium, mmol/l (99%)	138.34± 3.88	139.0 (4.0)	139.0 (3.0)	0.183	139.0 (3.25)	139.63 ± 2.52	139.34 ± 2.91	140.0 (3.0)
Potassium, mmol/l (99%)	4.57 ± 0.26	4.3 (0.6)	4.35 ± 0.58	0.720	4.2 (0.73)	4.28 ± 0.53	4.36 ± 0.52	4.31 ± 0.54
Calcium, mmol/l (98%)	2.28 (0.15)	2.29 (0.13)	2.31 ± 0.12	0.147	2.29 (0.17)	2.33 (0.14)	2.35 ± 0.13	2.34 ± 0.13
			1		-		1	
Systolic blood pressure, mmHg (63%)	132.93 ± 17.08	129.14 ± 21.9	139.54 ± 21.46	<0.0001	140.89 ± 25.87	136.78 ± 17.84	138.63 ± 23.21	138.12 ± 18.65
Diastolic blood pressure, mmHg (67%)	79.15 ± 11.76	73.79 ± 13.36	74.96 ± 13.45	<0.0001	73.16 ± 11.98	78.16 ± 13.09	80.68 ± 15.18	74.08 ± 13.73
Heart rate, beat/min (65%)	81.38 ± 14.28	73.69 ± 14.74	76.47 ± 16.72	0.0008	67.35 ± 9.63	75.31 ±14.1	75.0 ± 8.8	74.64 ± 18.15
Oxygen saturation, % (52%)	98.1 ± 1.75	96.49 ± 5.05	96.22 ± 3.0	<0.0001	96.36 ± 2.87	96.69 ± 2.87	97.89 ± 1.62	96.13 ± 4.66
LV end diastolic volume, ml (23%)	155.0 ± 61.89	152.46 ± 53.52	106.7 ± 26.52	< 0.0001	149.0 ± 16.97	124 ± NAN*	155.0 ± NAN *	110.83 ± 27.98
LV mass systolic, g (1 %)	176.7 ± 53.0	265.2 ± 155.2	225.2 ± 74.5	<0.0001	118.9 ± nan*	NAN *	210.3 ± 158.0	111.7 ± 89.9
LV ejection fraction, % (100%)	60.4 ± 3.9	44.2 ± 11.5	58.0 ± 4.9	<0.0001	55.5 ± 2.1	60.5 ± 0.7	61.5 ± 2.1	55.3 ± 4.1
LV internal diameter at end diastole, cm/m <sup>2</sup> (59%)	2.46 ± 0.24	2.71 ± 0.5	2.46 ± 0.36	0.0002	2.36 ± 0.26	2.46 ± 0.28	2.32 ± 0.24	2.45 ± 0.35
LV stroke volume, ml (4%)	92.5 ± 34.78	65.52 ± 19.78	55.0 ± 4.36	<0.0001	82.0 ± 5.66	75.0 ± NAN *	93.0 ± NAN *	64.2 ± 19.7
LV outflow tract velocity time integral diameter, cm (20%)	2.13 ± 0.28	2.16 ± 0.24	2.17 ± 0.34	0.1126	2.03 ± 0.2	2.14 ± 0.24	2.13 ± 0.12	2.07 ± 0.23

It is made available under a CC-BY-NC-ND 4.0 International license .

1		1	1		1	I	1	
LV end systolic	62.5 ±	87.32 ±	42.67 ±	0.1708	66.5 ±	49.0 ±	62.0 ±	49.4 ±
volume, ml (22%)	27.2	42.81	3.21		12.02	NAN *	NAN *	10.45
I A systolic volume, m	60.0 +	86.47 +	143.67 +	< 0.0001	120.5 +	112.0	69.0 +	70.33 +
(31%)	19.52	38 77	70.44	1010001	28 99	+ NAN	NAN *	21.4
(31/0)	13.32	50.77	70.44		20.55	*		21.7
TR max PG, mmHg	26.7 ±	29.4 ±	34.16 ±	< 0.0001	37.2 ±	24.9 ±	26.3 ±	32.3 ±
(80%)	10.2	11.2	12.9		13.8	10.18	8.3	11.4
E/e' lateral ratio	7.26 ±	10.70 ±	11.59 ±	< 0.0001	13.54 ±	11.70	9.35 ±	12.87 ±
(50%)	3.11	C 07	F OC		4.59	± 5.16	3.48	7.27
		6.07	5.96					
E/e' septal ratio	9.75 ±	14.51 ±	14.37 ±	< 0.0001	16.83 ±	14.77	11.5 ±	16.04 ±
(50%)	4.99		5.6		5.44	±6.2	4.52	7.53
		7.71						
RV V1 max, cm/sec	82.28 ±	71.98 ±	80.41 ±	0.0001	95.37 ±	80.87	71.34 ±	77.79 ±
(6%)	17.7	22.65	19.01		12.52	±	9.96	18.88
						17.42		
RV V1 mean, cm/sec	47.04 ±	47.38±	52.03 ±	0.0048	53.5 ±	59.05	48.65 ±	50.6 ±
(4%)	5.91	14.19	11.62		10.47	± 5.18	6.76	9.53
Mitral valve E/A ratio,	1.08 ±	1.37 ±	1.13 ±	< 0.0001	1.23 ±	0.9 ±	0.98 ±	1.04 ±
(84%)	0.42	0.07	0.61		0.76	0.34	0.36	0.4
Mitral regurgitation	483.46 ±	495.48 ±	502.84 ±	0.021	592.08	553.39	NAN	505.68
max velocity, cm/sec	68.77	88.56	93.06		± 98.05	± 31.3		±
(10%)								119.98
Tricuspid	233.23 ±	264.47 ±	274.1 ±	< 0.0001	310.38	254.82	239.73	277.2 ±
regurgitation max	31.74	56.62	56.34		± 61.48	±	± 41.81	50.81
velocity, cm/sec						53.76		
(80%)								

**Table 1. Baseline characteristics of patients.** The mean and SD (standard deviation) were obtained where the predictor distribution follows a normal distribution, whereas for predictors with a skewed distribution, the median and interquartile range (25<sup>th</sup>-75<sup>th</sup>) were used to report the statistics. To evaluate the distributional differences between cases and controls, the Mann-Whitney U test or the t test was acquired, where appropriate. Values in parentheses next to each predictor name indicate the data availability percentage.

\* Constraint-free assumption on our test sets resulted in predictors with either a singular value or a high proportion of missing values. In such cases, the computation of common statistics was not pragmatic and hence the NAN value (Not a Number) was reported, instead.

\*\* This predictor is only computed in the test cohort to enable the comparison with the H2FPEF score.

# 92.45% of HFpEF cases and controls had a BNP or pro-BNP level available.

Set I: patients with normal EF, no/normal BNP record, a HF ICD10 code and at least one HF and dyspnea reference in their EHR.

It is made available under a CC-BY-NC-ND 4.0 International license .

Set II: patients with normal EF, no/normal BNP record, no HF diagnostic code and at least one HF and dyspnea reference in their EHR.

Set III: patients with normal EF, no BNP record, no HF diagnostic code nor HF reference in the EHR, at least one report of dyspnea in their EHR.

Set IV: patients with normal EF, raised BNP result with HF and dyspnea reference in their EHR but no HF diagnosis documented

(*HF*: heart failure, *EF*: ejection fraction, *rEF*: reduced *EF*, *BNP*: brain-natriuretic peptide test, *EHR*: electronic health record).

The following ICD10 codes were used to define the comorbidities:

*Hypertension: 110-115, 160-169; Diabetes mellitus: E10-E14; Atrial fibrillation: 148; Pulmonary hypertension: 127; Kidney Disease: N18, N28, 112-115* 

It is made available under a CC-BY-NC-ND 4.0 International license .

	Control set	f1_macro ± 95% CI	f1_weighted ± 95% CI	AUROC ± 95% CI
Structured	Non-HF	84.05 ± 2.7	$84.18 \pm 2.7$	92.04 ±1.4
Signature				
	HFrEF	75.75 ± 2.1	$87.22 \pm 1.42$	90.31 ± 3.5
Unstructured	Non-HF	98.81 ± 1.3	98.82 ± 1.3	99.7 ± 0.5
Signature				
	HFrEF	$78.59 \pm 4.9$	88.99 ± 2.1	94.38 ± 1.4
combined	Non-HF	98.57 ± 1.4	98.59 ± 1.4	99.8 ± 0.3
signature	HFrEF	$83.03 \pm 2.8$	90.91 ± 1.6	95.67 ± 2.0

 Table 1. Multivariable model performance using the 5-fold cross-validation in derivation dataset.

It is made available under a CC-BY-NC-ND 4.0 International license .

		Unstructured	Structured data			
		data				
	Model	Symptoms	Echocardiography	Vitals	Age &	Lab results
			parameters		Sex	
Summed	HFpEF vs	0.953	0.036	0.011	0.033	< 0.001
importance	non-HF					
of grouped	HFpEF vs	0.551	0.334	0.115	0.058	< 0.001
features						
	HFrEF					

 Table 1. Additive SHAP feature importance for each category of predictors in the combined signatures.

It is made available under a CC-BY-NC-ND 4.0 International license .

	Performance	H2FPEF <sup>16</sup> ,	Combined	Combined	Aggregate	Scoring
	metric	%	non-HF signature, %	HFrEF signature, %	model score, %	Agreement
						(HFrEF and
						non_HF)
Test	AUROC	0.77	0.86 (± 0.002)	0.85 (± 0.001)	<b>0.90</b> (± <b>0.002</b> )	
set	(95% CI)					0.3
	AP	0.53	0.70	0.66	0.74	

**Table 1. Multivariable model performance in independent test cohort.** The 95% CI is reported using bootstrapping in a thousand of iterations.

\*: HFpEF annotation agreement between the two scoring systems using Cohen's kappa statistics (python 3, Sklearn v.0.22).

AUROC: area under receiver operative curve, AP: average precision, CI: confidence interval in bootstrapped samples